{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:31:45Z","timestamp":1781850705420,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.ijantimicag.2008.08.004","type":"journal-article","created":{"date-parts":[[2008,10,3]],"date-time":"2008-10-03T08:43:31Z","timestamp":1223023411000},"page":"194-200","source":"Crossref","is-referenced-by-count":93,"title":["Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data"],"prefix":"10.1016","volume":"33","author":[{"given":"Judith","family":"Sendzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Lode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Stahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2008.08.004_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-4274(77)90016-9","article-title":"Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids","volume":"1","author":"Ingham","year":"1977","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00204-002-0412-0","article-title":"Children as a special population at risk\u2014quinolones as an example for xenobiotics exhibiting skeletal toxicity","volume":"77","author":"Stahlmann","year":"2003","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib3","series-title":"Quinolone antimicrobial agents","first-page":"439","article-title":"Effects on connective tissue structures","author":"Stahlmann","year":"2003"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib4","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1128\/AAC.46.6.1755-1759.2002","article-title":"Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats","volume":"46","author":"Lozo","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib5","series-title":"40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17\u201320 September 2000; Toronto, Canada","article-title":"Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats","author":"Riecke","year":"2000"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib6","first-page":"50","article-title":"Effect of ciprofloxacin on growing cartilage in albino rat pups","volume":"18","author":"Channa","year":"2006","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib7","unstructured":"Bristol-Myers Squibb Company. Full prescribing information, Tequin\u2122, January 2006."},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib8","unstructured":"Ortho-McNeil Pharmaceutical Inc. Full prescribing information, Levaquin\u00ae, September 2007. http:\/\/www.levaquin.com [accessed 11 August 2008]."},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1529-0131(200106)45:3<235::AID-ART254>3.0.CO;2-7","article-title":"Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998","volume":"45","author":"Van der Linden","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib10","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMicm061227","article-title":"Images in clinical medicine. Quinolone-associated rupture of the Achilles\u2019 tendon","volume":"357","author":"Vyas","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2125.1999.00016.x","article-title":"Achilles tendinitis associated with fluoroquinolones","volume":"48","author":"van der Linden","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/019262339502300315","article-title":"Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats","volume":"23","author":"Kato","year":"1995","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.44.2.261-266.2000","article-title":"Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet","volume":"44","author":"Shakibaei","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tox.2005.04.002","article-title":"Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells","volume":"212","author":"Sendzik","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib15","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1128\/AAC.43.12.2915","article-title":"Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice","volume":"43","author":"Simonin","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/AAC.38.2.243","article-title":"Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents","volume":"38","author":"Hayem","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib17","doi-asserted-by":"crossref","first-page":"13289","DOI":"10.1074\/jbc.M010859200","article-title":"Inhibition of mitogen-activated protein kinase kinase induces apoptosis of human chondrocytes","volume":"276","author":"Shakibaei","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.taap.2007.08.025","article-title":"Ofloxacin induces apoptosis in microencapsulated juvenile rabbit chondrocytes by caspase-8-dependent mitochondrial pathway","volume":"226","author":"Sheng","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.106.118224","article-title":"Apoptosis in microencapsulated juvenile rabbit chondrocytes induced by ofloxacin: role played by \u03b21-integrin receptor","volume":"322","author":"Sheng","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1128\/AAC.39.9.2013","article-title":"Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy","volume":"39","author":"Stahlmann","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s002040050272","article-title":"Integrins on joint cartilage chondrocytes and alterations by ofloxacin or magnesium deficiency in immature rats","volume":"70","author":"F\u00f6rster","year":"1996","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002239900328","article-title":"Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity","volume":"61","author":"Vormann","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib23","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.01175-06","article-title":"Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats","volume":"51","author":"Pfister","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0022-3859.32220","article-title":"Ofloxacin-induced reversible arthropathy in a child","volume":"53","author":"Dolui","year":"2007","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib25","first-page":"735","article-title":"Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis [in French]","volume":"56","author":"Pertuiset","year":"1989","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-199701000-00036","article-title":"Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use\u2014safety report","volume":"16","author":"Hampel","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00006454-199701000-00032","article-title":"Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis","volume":"16","author":"Schaad","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00006454-200206000-00009","article-title":"Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin","volume":"21","author":"Yee","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00006454-200201000-00004","article-title":"Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin","volume":"21","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(05)67290-X","article-title":"Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial","volume":"366","author":"Saha","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib31","unstructured":"Bayer. Full prescribing information, Cipro\u00ae, October 2004."},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1086\/431584","article-title":"Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and\/or AOM treatment failure","volume":"41","author":"Pichichero","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.inf.0000095193.42502.d1","article-title":"Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure","volume":"22","author":"Arguedas","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib34","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/498318","article-title":"Gatifloxacin therapy for children: turn on the light","volume":"41","author":"Echols","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/INF.0b013e3180cbd2c7","article-title":"Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia","volume":"26","author":"Bradley","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib36","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/01.inf.0000246828.13834.f9","article-title":"An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media","volume":"25","author":"Arguedas","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","article-title":"Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders","volume":"26","author":"Noel","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib38","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/INF.0b013e3180cc20e4","article-title":"Will fluoroquinolones ever be recommended for common infections in children?","volume":"26","author":"Schaad","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1086\/341900","article-title":"The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?","volume":"35","author":"Mandell","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/bdrb.10012","article-title":"Species comparison of postnatal bone growth and development","volume":"8","author":"Zoetis","year":"2003","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1439787","article-title":"Saltation and stasis: a model of human growth","volume":"258","author":"Lampl","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/en.134.3.1317","article-title":"Linear growth in the rabbit is continuous, not saltatory","volume":"134","author":"Klein","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/03014469500004012","article-title":"No evidence for saltation in human growth","volume":"22","author":"Hermanussen","year":"1995","journal-title":"Ann Hum Biol"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib44","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1210\/en.137.12.5197","article-title":"Is growth saltatory? The usefulness and limitations of frequency distributions in analyzing pulsatile data","volume":"137","author":"Johnson","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006454-199501000-00001","article-title":"Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission","volume":"14","author":"Schaad","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib46","series-title":"The quinolones","first-page":"455","article-title":"Use of the quinolones in pediatrics","author":"Schaad","year":"2000"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1473-3099(03)00736-9","article-title":"Fluoroquinolones in paediatrics: a risk for the patient or for the community?","volume":"3","author":"Gendrel","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib48","series-title":"Quinolone antimicrobial agents","first-page":"343","article-title":"Quinolones in pediatrics","author":"Ghaffar","year":"2003"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.idc.2005.05.005","article-title":"Fluoroquinolone antibiotics in infants and children","volume":"19","author":"Schaad","year":"2005","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.mop.0000192520.48411.fa","article-title":"The use of fluoroquinolones in children","volume":"18","author":"Leibovitz","year":"2006","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.ijantimicag.2008.08.004_bib51","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1542\/peds.2006-1722","article-title":"The use of systemic fluoroquinolones","volume":"118","author":"Committee of Infectious Diseases","year":"2006","journal-title":"Pediatrics"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T19:24:11Z","timestamp":1631906651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857908003531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0924857908003531"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.08.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}